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Background and Aims: The aims of the present study were to determine the expression
of urotensin II (UII), urotensin-II related peptide (URP), and their receptor (UT) in stable and
unstable carotid atherosclerosis, and determine the effects of UII on human aortic smooth
muscle cell (SMCs) calcification.
Methods and Results: We examined UII, URP, and UT protein expression in 88 carotid
endarterectomy specimens using immunohistochemistry. Expression of UII, URP, and
UT was more evident in unstable compared to stable plaques (P < 0.05). Multivariate
Spearman correlation analyses revealed significant positive correlations between UII,
URP and UT overall staining and presence of calcification, severity of stenosis and
inflammation (P < 0.05). Subjects undergoing carotid endarterectomy had significantly
higher plasma UII levels, as assessed by ELISA, when compared with normolipidemic
healthy control subjects (P < 0.05). Incubation of human aortic SMCs cultured in
phosphate media with varying concentrations of UII resulted in a significant increase
in calcium deposition and alkaline phosphatase activity. UII also significantly increased
β-catenin translocation and expression of ALPL, BMP2, ON, and SOX9 (P < 0.05).
Incubation of cells with phosphate medium alone increased the expression of the pre-UT
and mature UT (P < 0.01), and addition of UII had a synergistic effect on pre-UT protein
expression (P < 0.001) compared to phosphate medium alone.
Conclusions: Upregulation of UII, URP, and UT in unstable carotid endarterectomy
plaques and plasma, and the stimulatory effect of UII on vascular smooth muscle cell
calcification suggest that the UII system may play a role in the pathogenesis of vascular
calcification and stability of atherosclerosis.
Keywords: immunohistochemistry, calcium, URP, UT, UII, urotensin II, urotensin II-related peptide, smoothmuscle
cells
INTRODUCTION
Atherosclerosis is a leading cause of death in Western societies, and is a major contributor to
several cardiovascular diseases such as myocardial infarction (MI) and stroke (Yusuf et al., 2002).
Turbulent blood flow is a known endothelial cell activator, thus contributing to the formation of
atherosclerotic plaques mainly in bifurcated blood vessels such as carotid arteries (Tsaousi et al.,
2011). Endothelial dysfunction due to alterations in blood flow and/or vascular injury is considered
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the first step in the pathogenesis of atherosclerosis (Libby,
2012). The latter is characterized by the accumulation of lipids
and fibrous lesions in large arteries (Lusis, 2000). Vascular
calcification occurs in advanced atherosclerotic lesions, and
is a marker of atherosclerosis associated with cardiovascular
pathologies such as hypertension, congestive heart failure,
hypertrophy, ischemia, myocardial infarction, and stroke
(Johnson et al., 2006; Demer and Tintut, 2008). Long-term
outcomes are worse in patients with calcified blood vessels (Shao
et al., 2010).
Urotensin II (UII) is a potent vasoactive peptide, first isolated
in the teleost fish Gillichthys mirabilis (Pearson et al., 1980), and
subsequently identified in human and other species (Coulouarn
et al., 1998; Ames et al., 1999; Elshourbagy et al., 2002). UII
possess a wide range of vasoactive properties depending on the
type of vessel and species (Itoh et al., 1988; Douglas et al.,
2000; Affolter and Webb, 2001). Urotensin II related peptide
(URP) is the endogenous and functional ligand for UII receptor
(UT) in rats and mice, and its expression has been shown
to be elevated in essential hypertension (Prosser et al., 2008).
UII and UT have been associated with multiple cardiovascular
pathologies such as congenital heart disease (Simpson et al.,
2006), ischemic reperfusion injury (Prosser et al., 2008), atrial
fibrillation (Zhang et al., 2009), and congestive heart failure
(Douglas et al., 2002; Dschietzig et al., 2002; Dai et al., 2008).
We were the first to demonstrate that atherosclerotic lesions of
the human carotid arteries and aorta have increased expression
of UII and UT compared to healthy vessels (Bousette et al.,
2004). In recent years, significant evidence has begun to emerge
about the role of the UT receptor system in atherosclerosis (Ross
et al., 2010). We have demonstrated that both the UT antagonist
SB657510A and UII gene deletion in atherosclerotic mice can
lead to several beneficial effects, including reductions in serum
cytokines, inflammatory adipokines, and adipogenesis, as well
as improvement in hypertension and glucose tolerance (You
et al., 2012). UT antagonist SB657510A also attenuates diabetes-
associated plaque development (Watson et al., 2013). Despite the
strong evidence implicating UII in atherosclerosis and associated
features such as hyperlipidemia, there are currently no studies
demonstrating a direct role for UII in vascular calcification.
In this study, we aimed to assess the tissue expression of UII,
URP, and UT, and the plasma levels of UII in relation to carotid
plaque stability, and presence of calcification, inflammation, and
lipid. We also determined the effect of UII on human aortic
SMCs differentiation, calcification, alkaline phosphatase (ALP)
enzyme activity, and signaling pathway of genes associated with
osteogenesis.
MATERIALS AND METHODS
Tissue Collection
Eighty-eight carotid plaque specimens were freshly collected
from patients who underwent carotid endarterectomy
procedures between 2009 and 2011. Summary of clinical
data for these patients is shown in Table 1. Venous blood
Abbreviations: SMCs, Smooth muscle cells.
samples were also collected from 55 of these patients (38 stable
and 17 unstable) as well as 44 normolipidemic healthy control
subjects into EDTA-containing tubes and were centrifuged
and stored at −80◦C for future analysis of plasma UII and
biochemical analysis in batches (Table 2). The degree of carotid
stenosis was assessed using 3D carotid ultrasound (Philips iu22).
This study was approved by the McGill Ethics Institutional
Research Board, and all patients provided written informed
consent.
TABLE 1 | Clinical characteristics of the carotid endarterectomy
specimens included in the immunohistochemical study.
Parameter Stable (N = 57) Unstable Statistical
(N = 31) difference
Age (years) 68.74±10.05 71.42± 7.61 NS
Sex (Number of females) 18 (31.6%) 6 (19.4%) NS
BMI (kg/m2) 26.95±3.97 26.65± 4.79 NS
TC (mmol/L) 3.68±1.04 3.72± 1.08 NS
TG (mmol/L) 1.72±0.96 1.70± 0.69 NS
HDL (mmol/L) 0.96±0.27 0.93± 0.27 NS
LDL (mmol/L) 2.00±0.95 2.01± 0.93 NS
Total Chol/HDL 4.04±1.36 4.13± 1.06 NS
ApoB (g/L) 0.74±0.24 0.77± 0.24 NS
ApoA1 (g/L) 1.23±0.24 1.26± 0.30 NS
ApoB/ApoA1 0.62±0.23 0.63± 0.20 NS
SBP (mmHg) 141.2±16.39 139.7± 17.60 NS
DBP (mmHg) 70.07±9.99 64.14± 9.98 NS
Stenosis (%) 84.5±10.51 86.07± 8.94 NS
Diabetes (Number of patients) 19 (33.3%) 8 (25.8%) NS
BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; ApoB, Apolipoprotein B; ApoA1, Apolipoprotein
A1; SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not significant.
TABLE 2 | Clinical characteristics of the carotid endarterectomy patients
vs. control subjects included in the ELISA study.
Parameter Carotid patients Control Statistical
(N = 55) (N = 44) difference
Age (years) 68.98±9.30 41.41± 15.37 P < 0.0001
Sex (Number of females) 15 (27.3%) 20 (45.5%) NS
BMI (kg/m2) 26.91±4.01 23.02± 3.29 P < 0.0001
TC (mmol/L) 3.68±1.01 4.90± 1.09 P < 0.0001
TG (mmol/L) 1.74±0.89 1.46± 0.76 NS
HDL (mmol/L) 0.95±0.26 1.23± 0.22 P < 0.0001
LDL (mmol/L) 1.97±0.94 1.16± 0.38 P < 0.0001
Total Chol/HDL 4.08±1.26 4.12± 1.27 NS
ApoB (g/L) 0.75±0.24 1.03± 0.25 P < 0.0001
SBP (mmHg) 140.8±18.3 117.2± 16.8 P < 0.0001
DBP (mmHg) 69.2±10.0 72.3± 10.5 NS
Statins (Number of patients) (38/55) (4/44) P < 0.0001
BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; ApoB, Apolipoprotein B; ApoA1, Apolipoprotein
A1; SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not significant.
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Immunohistochemistry
The paraffin-embedded carotid specimen blocks were cut into 4–
5 µm sections using a microtome and placed on glass slides. The
immunohistochemical technique used here had previously been
described (Pearson et al., 1980). Five sections were examined per
lesion (for each antiserum). A total of 6 images were analyzed per
section.
The antibody used for the URP immunostaining studies was
purchased from Phoenix Pharmaceuticals H-071-17, and does
not cross react with human UII. The antibodies against UII
and UT used have been previously described (Douglas et al.,
2002; Bousette et al., 2006b). Additional sections were stained
for α-smooth muscle actin (smooth muscle marker, Cedarlane
CLT9000, 1/500) and Mac-2 (macrophage marker, Cedarlane
CL8942AP, 1/2500).
Carotid plaques were semi-quantitatively assessed blindly by
two independent vascular pathologists for calcification, fibrosis,
inflammation, lipid, microvessels, hemorrhage, thrombus, cap
infiltration with inflammatory cells and overall plaque instability,
using well-established scales, including the widely used American
Heart Association (AHA) plaque classification (Stary et al., 1995;
Lovett et al., 2004). All plaques were classified as either AHA
type V or type VI and lesions that were classified as type V were
considered as stable and those classified as type VI, considered
unstable. Immunostaining was assessed using Image J by two
independent observers.
Measurement of Circulating UII Levels
In all 55 subjects who underwent carotid endarterectomy, as
well as in the normolipidemic healthy control subjects UII levels
were measured using human urotensin II ELISA kit (PromoKine,
catalog number: PK-EL-K101, Germany) in accordance with
the manufacture’s manual. The specificity of the ELISA kit had
previously been described (Al Kindi et al., 2014).
In vitro Studies
In vitro Calcification Experiments
Human aortic SMCs were cultured in Medium-231
(ThermoFisher) including Smooth Muscle Cell Differentiation
Supplement (ThermoFisher) in the presence of varying
concentrations of UII (0, 10, 50, 100 nM), 100 nM UII+ varying
concentrations (0, 1, 10 µM) of UT antagonist SB657510A
(kindly offered by GSK, USA), 0, 10, 50, 100 nM of URP, and 100
nM URP + 10 µM of UT antagonist SB657510A and 100 nM
of URP for 2 weeks. Calcium content was measured using the
Arsenazo III method. Cells were assayed in triplicates in 96 well
plates.
Briefly, cells were washed three times with 2 ml PBS
(Phosphate-Buffered Saline, Life Technologies) per well for 5 min
each wash. Cells were then incubated with 250 µL of 0.6N HCl
for 24 h at room temperature (RT) and Ca2+ was measured
using colorometric Arsenazo III method. To the remaining cells,
protein lysis buffer was added (100 µL of 0.1N NaOH with 0.1%
SDS) for 20 min at RT. Cells were transferred to Eppendorf tubes
and centrifuged for 5 min at 4◦C at 15,000 rpm. The supernatants
were removed and stored at −80◦C for subsequent protein
measurement, for the normalization of Ca2+measurements.
In vitro ALP Assay
SMCs were incubated for 7 days in the following conditions:
DMEM alone. Forty-eight hours after incubation under the
different media conditions, ALP activity in human aortic smooth
muscle cell media was assessed using Alkaline Phosphatase
Activity Colorimetric Assay Kit (BioVision) according to
manufacturer protocols. Eighty microliters of media was added
to each well. Eighty microliters of fresh media were also added
to separate wells to use as a sample background control. Twenty
microliters of Stop Solution was added to the background
control. Then, 50 µL of 5 mM p-nitrophenyl phosphate (pNPP)
was added to each well and reaction was incubated for 1 h at
25◦C, protected from light. Twenty microliters of Stop Solution
was added to each sample and standard well to stop the reactions.
O.D. was measured at 405 nm in micro plate reader. Using
standard curve, ALP activity in the media of each sample was
calculated and is expressed in Glycine Units. Glycine Units are
defined as the amount of enzyme causing hydrolysis of 1 µmol of
pNPP per minute at pH 9.6 and 25◦C.
Effect of Phosphate Medium on UT Protein
Expression in SMCs
SMCs were incubated in either DMEM, DMEM+UII (100
nM), Pi-DMEM (phosphate: 2.6 mmol/l), or Pi-DMEM+UII
(phosphate: 2.6 mmol/l, UII: 100 nM) for 7 days. The medium
was changed every 2–3 days. After two washes in PBS buffer,
the cells were placed in lysis buffer for 15 min on ice. The
solutions were transferred into eppendorf tubes and centrifuged
at 8000 rpm for 5 min. UT expression was detected withWestern
blot (primary antibody dilution 1:1000, and secondary antibody
dilution 1:5000). UT antibody used was as previously described
(Bousette et al., 2006a).
GAPDH was as internal standard. Image J was used to quantity
UT expression.
Effect of UII on SMC Proliferation
Vascular SMCs were incubated with phosphate medium with or
without 10 nM UII for 4 and 7 days. Cells were then fixed in 4%
paraformaldehyde and stained with antiserum to α-SMC actin
using the avidin-biotin-peroxidase method described above. The
numbers of α-SMC actin-positive cells were quantified using
Image J.
RT-PCR Analyses
Vascular SMCs were treated with or without 100 nM human
UII peptide (Sigma) for 24 h in osteogenic medium (OSM).
Cells in 24-well plate were washed with cold PBS, then total
RNA were isolated by using RNeasy mini kit(Qiagen). One
microgram RNA was used for the first strand cDNA synthesis
using iScript Select cDNA synthesis kit (Bio-Rad), and qPCR
performed using Advanced qPCR Master mix HI-ROX(Wisent)
on StepOneTM Plus (Applied Biosystems) for various osteogenic
mediators. Gene expression level was calculated against a control
standard curve generated by housekeeping gene: GAPDH,
relative expression level is presented as relative ratio normalized
against sample GAPDH level. DMEM medium (DM): Gibco
DMEM with high glucose containing 10% FBS, 1% Penicillin,
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1% Streptomycin; Osteogenic medium: full DMEM medium
with calcification reagent, 2 mM phosphate buffer and 0.2 mM
ascorbic acid. N = 4 per experiment.
To assess UII, URP, and UT mRNA expression in carotid
plaques, total RNAs (total 20 IHC matched samples, stable
cases = 10, unstable cases = 10) were extracted from surgically
removed carotid plaques using TRIzol(ThermoFisher) and
RNeasy mini kit(Qiagen). First strain cDNAs were synthesized
using 1µg total RNAwith iScript Select cDNA synthesis kit (Bio-
Rad), and qPCR performed using Advanced qPCR Master mix
HI-ROX(Wisent) on StepOneTM Plus (Applied Biosystems).
GAPDH was used as internal control, relative gene expression
was calculated using GeneStudy software (Bio-Rad).
Effect of UII on β-Catenin Nuclear Translocation
Vascular SMCs were seeded in duplicates of 100 mm petri dishes
and were pre-incubated in osteogenic medium for 4 days, then
UII (100 nM) or URP (100 nM) was added into medium for 20
h. Nuclei were extracted with Nuclear Extract Kit (Active Motif,
CA USA, cat#40010). Nuclear protein was loaded on SDS-PAGE,
and β-catenin was detected by Western blot using a polyclonal
antiserum (HPA029159, Sigma). The membranes were probed
with antiserum to TFIIB as an internal standard (Santa Cruz).
Statistical Analysis
Multivariate Spearman analysis was used to assess correlations
between UII, URP and UT immunohistochemical stainings
with the histologic features of carotid atherosclerosis (degree
of stenosis, extent of calcification, fibrosis, inflammation, lipid
score, microvessels, hemorrhage, thrombus, and cap instability)
and clinical parameters [age, sex, body mass index (BMI), total
cholesterol, triglycerides, HDL, LDL, Total Chol/HDL, ApoB,
ApoA1, ApoB/ApoA1, stenosis, and blood pressure]. One-way
ANOVA was used to assess UII, URP, and UT immunostaining
in stable compared to unstable carotid plaques, plasma UII
measurements in stable and unstable carotid endarterectomy
patients as well as when comparing plasma UII values to controls,
and the significance of the differences in SMC calcification
and ALP activity for different stimulation conditions. For the
clinical comparison of patient populations, unpaired t-test was
performed to determine the statistical significance of continuous
variables between the groups. Fisher’s exact test was performed to
determine the statistical significance of the categorical variables
(sex, hypertension, and diabetes) between the two groups.
Statistical analyses were performed using GraphPad Prism
software version 6.0d (GraphPad Software Inc., La Jolla, CA,
USA). P < 0.05 was considered significant.
RESULTS
UII Immunohistochemistry
UII immunostaining was highest in myointimal cells, followed
by media SMCs and foam cells (Figures 1A,E,F). Importantly,
UII immunostaining intensity was significantly elevated in
activated myointimal cells compared to myointimal cells that
were not classified as activated (P < 0.0001). Semi-quantitative
analyses of UII immunostaining intensity showed that UII
immunoreactivity was significantly higher in osteoblast, medial
smooth muscle cells and microvessels in unstable compared to
stable carotid plaques (P < 0.05; Figures 1A–D; Supplemental
Figure 1). Multivariate Spearman correlation analysis revealed
significant correlations between overall UII immunoreactivity
and diastolic blood pressure (r = 0.2410; P < 0.05), calcification
(r = 0.268; P < 0.05), remodeling (r = 0.339, P < 0.01),
inflammation (r = 0.5077; P < 0.0001), lipid (r = 0.353; P <
0.001), URP immunoreactivity (r = 0.671; P < 0.0001), and UT
immunoreactivity (r = 0.440; P < 0.0001).
URP Immunohistochemistry
URP immunostaining was evident in endothelial, myointimal,
medial SMCs, and inflammatory cells. URP was also
present in microvascular endothelial cells, foam cells and
osteoblasts (Figures 1G–L). Semi-quantitative analyses of URP
immunostaining intensity showed that URP immunoreactivity
was significantly elevated in endothelial and foam cells of
unstable compared to stable plaques (P < 0.05; Figures 1G–L;
Supplemental Figure 1). Multivariate Spearman correlation
analysis revealed significant correlations between overall URP
immunoreactivity and calcification (r = 0.261; P < 0.0127),
fibrosis (r = 0.276; P < 0.01), remodeling (r = 0.2793; P < 0.05),
inflammation (r= 0.489; P < 0.0001), lipid (r= 0.304; P < 0.01),
and UT immunoreactivity (r = 0.4; P < 0.001).
UT Immunohistochemistry
UT cellular expression showed strongest immunostaining in
myointimal cells followed by medial SMCs (Figure 1M).
Semi-quantitative analyses of UT immunostaining showed
no significant differences in stable compared to unstable
carotid plaques (Supplemental Figure 1). Multivariate Spearman
correlation analysis revealed significant correlations between UT
immunoreactivity and BMI (r = −0.2431; P < 0.05), carotid
stenosis (r = 0.2669; P < 0.05), calcification (r = 0.381; P <
0.001), fibrosis (r = 0.2175, P < 0.05), remodeling (r = 0.297;
P < 0.01), and inflammation (r = 0.292; P < 0.01).
Negative control sections immunostained with the non-
immune sera or preabsorped with the respective antigens did not
show immunoreaction (Figure 1N).
RT-PCR
UII, URP, and UT mRNA expression was also assessed in stable
and unstable carotid plaques however there was no significant
difference between the two groups in any of the three molecules
(Supplemental Figure 2).
Plasma UII Levels
The mean age of the carotid endarterectomy patients included in
the measurement of plasma UII was 69.0 ± 9.3 years and was
significantly higher than the control group (41.4 ± 15.4 years;
P < 0.0001). Plasma UII levels were still significantly elevated
in carotid endarterectomy patients compared to an age-matched
control subgroup (n = 10; P < 0.0001). BMI, LDL, systolic
blood pressure, and statin use were significantly higher in the
carotid endarterectomy group; while total cholesterol, HDL, and
ApoB were significantly lower when compared with that of the
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FIGURE 1 | Representative immunohistochemical localization of UII,
UT, and URP in human carotid plaque specimens. (A) UII
immunoreactivity in stable carotid plaque: low intensity UII immunostaining
(Continued)
FIGURE 1 | Continued
in calcification (right arrow) and higher intensity immunostaining in myointimal
cells (left arrow). (B) Strong UII immunoreactivity in calcified lesions of unstable
carotid plaque. (C) UII staining in microvessels (bold arrow) and myointimal
cells (dashed arrow) in stable carotid plaque. (D) Abundant UII staining in
microvessels of unstable plaque. (E) UII staining in media SMCs of unstable
plaque. (F) UII staining in foam cells of unstable plaque. (G) URP
immunoreactivity in lipid core and surrounding cholesterol clefts (arrows) in
stable carotid plaque. (H) Strong URP immunoreactivity in lipid core of
unstable carotid plaque. (I) URP immunoreactivity in fibrosis of stable plaque.
(J) Elevated URP immunoreactivity in fibrosis of unstable plaque. (K) URP
staining in microvessels of unstable plaque. (L) URP staining in inflammatory
cells of unstable plaque. (M) Abundant UT immunoreactivity in myointimal cells
(right arrow) and calcium deposition (left arrow). (N) Negative control section of
lipid and myointimal cells immunostained with normal serum showing no
immunoreactivity.
control group (see Table 2 in Materials and Methods). The mean
(±SEM) plasma level of UII in carotid endarterectomy patients
was significantly elevated (1194.0 ± 83.8 pg/ml) compared to
the control group (252.7 ± 13.9 pg/ml; P < 0.0001). Plasma UII
levels were still significantly elevated in carotid endarterectomy
patients compared to an age-matched control subgroup (293.1±
36.92 pg/ml, n = 10; P < 0.0001). Correlation studies revealed
significant correlations between plasma UII and age (r = 0.597, P
< 0.0001), BMI (r = 0.453, P < 0.0001), systolic blood pressure
(r = 0.5130, P < 0.0001), total cholesterol (r = −0.35; P <
0.001), triglycerides (r = 0.274, P < 0.01), HDL (r =−0.439, P <
0.0001), and LDL (r = 0.558, P < 0.0001).
In vitro Data
Vascular SMCs were incubated in phosphate medium for 2
weeks with varying concentrations of urotensin II (0, 10, 50,
100 nM). SMC calcification was assessed as the ratio of calcium
(µg)/total protein (mg). While supplementation with UII had no
significant effect on calcification in normal media, UII appears
to be potentiating the effects of phosphate medium on SMC
calcification in a dose-dependent manner. Phosphate medium
+ 100 nM UII had significantly elevated calcium deposition
compared to phosphate medium alone (P = 0.0167, Figure 2).
URP at 100 nM concentration showed the strongest stimulation
of SMC calcification (P = 0.0376, Figure 2).
UII and URP stimulatory effect on SMC calcification were
significantly reduced in the presence of SB657510A at 10
µM concentration (P = 0.0051 and P = 0.0191; respectively,
Figure 2). This demonstrates that UII and URP effects on SMC
calcification are mediated by signaling through UT.
There was a significantly reduced number of α-smooth
muscle actin (α-SMA) positive cells 4 days after incubation
with phosphate medium containing 100 mM UII compared to
phosphate medium alone (data not shown; P < 0.01). At 7 days
there was no difference between phosphate medium with or
without UII. Moreover, incubation of SMCs with UII as well as
URP significantly induced β-catenin nuclear translocation (P <
0.05) (Figure 3).
Assessment of UT protein expression in SMCs following
incubation with phosphate medium revealed a significant
increase in protein expression of UT, both mature and immature
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FIGURE 2 | UT Antagonist SB657510A (SB) inhibits UII and URP
induced SMC calcification. SMCs were incubated in phosphate medium
(PI) for 14 days with 100 nM UII or 100 nM URP, in the presence and absence
of UT antagonist (SB) at concentration 10 µM. UII and URP stimulatory effect
on SMC calcification was abolished in the presence of SB657510A. *P < 0.05
(n = 4 per experiment).
forms (Figure 4). UII stimulation potentiates the phosphate
medium-induced increase in pre-UT as the phosphatemedium+
UII stimulated cells had significantly elevated expression of pre-
UT compared to phosphate medium alone. However, this was
not the case with the mature form of UT, where both phosphate
alone and phosphate+UII had significantly elevated mature UT
protein expression compared to control conditions.
Incubation of SMCs with phosphate medium significantly
increased the expression of various osteogenic mediators.
Addition of 100 nM UII for 24 h significantly augmented the
expression of ALPL, BMP2, osteonectin (ON), SOX9, collagen
1A1, collagen 3A1, and α-SMC actin (P < 0.01) (Figure 5).
Expression ofMsx2 and Runx2 were not significantly altered.
DISCUSSION
There is an abundance of evidence showing that carotid
atherosclerosis is associated with increased risk of stroke and
mortality, particularly in elderly patients (Stary et al., 1995; Störk
et al., 2004). There is currently a great need for clinically-relevant
serum and tissue biomarkers of carotid atherosclerosis, especially
those that can distinguish between stable and unstable carotid
plaques. This will contribute to a greater understanding of the
pathogenesis of this process and ideally, be a useful tool in the
selection of patients for surgical intervention. In this study, we
aimed at determining the serum level of UII and tissue expression
of UII, URP, and UT in carotid plaque specimens in relation to
their stability and to determine if UII plays a role in vascular SMC
calcification.
Circulating levels of UII were higher in carotid
endarterectomy compared with normal control subjects. We
found significant differences in UII and URP immunostaining
in unstable compared to stable plaques. Our in vitro studies
revealed that UII and URP had a significant dose-dependent
FIGURE 3 | UII and URP induce SMC nuclear translocation of
β-catenin. SMCs were incubated in phosphate medium(PI) in the presence
and absence of 100 nM UII or 100 nM URP. Incubation of SMCs with UII and
URP each significantly induced β-catenin nuclear translocation. Nuclear
β-catenin protein expression was normalized to the expression of TFIIB
(Transcription Factor IIB). *P < 0.05 (n = 6 per experiment). (A) Western blot
visualization. (B) Relative β-catenin quantification normalized to the expression
of TFIIB (Transcription Factor IIB).
effect on SMC calcification in the presence of phosphate
media and that this effect was abolished in the presence of UT
antagonist SB657510A. UII stimulation also increased ALP
activity and a number of osteogenic mediators in SMCs in the
presence of phosphate media. Together, these results suggest
that the UII stimulates the osteogenic differentiation of SMCs,
and suggest a role for the UII system in the pathology of carotid
plaques.
To our knowledge, there is currently little evidence for
the role of URP in any features of atherosclerosis, and this
is the first study profiling its tissue expression in carotid
atherosclerosis. The major difference in URP expression in
stable compared to unstable plaques are that unstable plaques
had significantly higher intensity in endothelial and foam cells.
URP immunoreactivity was also very strong in osteoblasts,
macrophages and lymphocytes and activated myointimal cells,
however this was not significantly different in stable compared
to unstable plaques. There is currently very little work on
differential expression of UII and URP. Studies in mice
have shown similar UII and URP expression in the nervous
system, skeletal muscle, testes, vagina, and gall bladder, and
differential expression in the seminal vesicles, heart, colon, and
thymus (Dubessy et al., 2008). Another study of spontaneously
hypertensive rats found elevated URP mRNA expression,
suggesting a potential role for URP in spontaneous hypertension
(Forty and Ashton, 2013). The differential cellular expression of
URP in unstable vs. stable carotid atherosclerosis suggests that
this may occur as either cause or effect in atherosclerotic disease
and warrants further investigation.
We have previously demonstrated that UII and UT
immunostaining is significantly elevated in atherosclerotic
human carotid arteries compared to control, citing
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FIGURE 4 | Phosphate medium induces increased protein expression
of UT. SMCs were incubated under one of the following conditions: DMEM
alone, DMEM + 100 nM UII, phosphate medium (Pi) alone or phosphate
medium (Pi) + 100 nM UII. Two different degree of glycosylated UT
(Upper-band and Lower-band) were detected around 60KD in SMCs.
Phosphate medium significantly increases the total UT and Upper-band
compared to DMEM and DMEM + UII conditions, *P < 0.01. UII stimulation
significantly increased UT expression in Pi medium compared to Pi medium
alone **P < 0.001. N = 4 for each condition. (A) Western blot visualization. (B)
Relative UT quantification normalized to the expression of GAPDH.
immunoreactivity in endothelial, smooth muscle, and
inflammatory cells (Bousette et al., 2004). In this study, we
analyzed tissue expression relative to the stability of carotid
plaques and found significantly elevated intensity in osteoblasts
and medial SMCs in unstable compared to stable plaques.
UII and UT immunoreactivities were also very strong in
inflammatory cells of both stable and unstable plaques but since
unstable plaques had significantly more inflammation, they had
greater overall UII and UT immunostaining in these cells. Given
that unstable plaques are associated with increased inflammation
and release of cytokines, it is reasonable to assume that the
increase in UII and UT is driven by inflammatory cytokines
such as IL-6, previously shown to induce the expression of
these molecules (Zhou et al., 2012). Further investigations using
animal models of unstable plaques are needed to determine the
exact role of UII and UT in atherosclerotic plaque stability.
ELISA measurements of plasma UII levels in the carotid
endarterectomy patients revealed elevated plasma UII compared
to controls; however, there was no significant difference
between plasma UII levels in stable and unstable patients.
We found significant positive correlations between plasma
UII and age, BMI, triglycerides, and systolic blood pressure,
and significant negative correlations with HDL and total
cholesterol. Our findings are consistent with previous studies
in hypertensive carotid endarterectomy demonstrating increased
UII and association with BMI, age and systolic blood pressure
(Cheung et al., 2004; Chen et al., 2009). The inverse correlation
between serum UII and total cholesterol and HDL can be
attributed to statin use in patients with carotid endarterectomy,
FIGURE 5 | UII stimulation of SMCs induces expression of osteogenic
markers. SMCs in phosphate medium (PI) were incubated with 200 nM UII for
24 h and expression of ALPL, BMP2, osteonectin, SOX9, collagen 1A1,
collagen 3A1, and α-smooth muscle cell actin were assessed by Real time
qPCR. Relative gene expression level was calculated against GAPDH level,
and data is presented as fold change of relative interested gene expression in
UII treated (UII). *P < 0.01 (n = 4 per experiment).
and further supported by our previous findings in experimental
animals (You et al., 2012, 2014). Our findings that plasma
UII is elevated in carotid atherosclerosis but not significantly
different in stable compared to unstable patients demonstrate the
importance of looking at tissue expression of UII and associated
proteins to get better insight into their roles in the pathogenesis
of carotid atherosclerosis.
This is the first study showing direct effects of UII and URP
on SMC calcification and osteogenic differentiation. Vascular
calcification occurs in very advanced atherosclerotic lesions
and is a marker for atherosclerosis associated with several
cardiovascular pathologies including hypertension, congestive
heart failure, cardiac hypertrophy and ischemia and increased
risk of myocardial infarction and stroke (Johnson et al., 2006;
Demer and Tintut, 2008). It has been previously demonstrated
that translocation of β-catenin and expression of skeletal
morphogen BMP2 mediate the osteogenic differentiation of
activated SMCs and this plays a crucial role in atherosclerotic
calcification (Boström et al., 1993; Montes de Oca et al., 2014).
Additionally, other osteogenic markers, osteonectin and SOX9,
have also been localized to atherosclerotic plaques suggesting
roles for them in the pathological calcification (Aigner et al., 2008;
Farrokhi et al., 2014). Here, we demonstrate that UII and URP, in
the presence of phosphate medium, stimulate calcium deposition
in SMCs. Furthermore, UII increased ALP activity, β-catenin
translocation, and increased expression of ALPL, BMP2,ON, and
SOX9, thus indicating osteogenic differentiation. Importantly, we
found that phosphate medium alone or with UII increased UT
protein expression, thus providing support for an important role
for the UII system in vascular calcification.
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Limitations of this study: Increasing the number of patients
included in the UII ELISA study may reveal differences
in serum UII in patients with stable compared to unstable
plaques. Additionally, further investigations should include the
correlation of urotensin II levels with both tissue and serum levels
of mediators of SMC osteogenic differentiation. Finally, the fact
that our study only addresses the relationship between UII, URP
and UT with atherosclerotic intimal calcification without any
investigation of medial vascular calcification that is commonly
seen in ESRD, diabetes, and elderly populations.
In summary, the present study demonstrates for the first
time two important findings; first, local expression of the
UII system in unstable carotid plaques is significantly higher
than in stable plaques, and second, in vitro UII in the
presence of phosphate medium induces ALP activity, β-
catenin translocation, osteogenic transdifferentiation and ectopic
calcium deposition in SMCs. A role for UII in inflammation
(Liang et al., 2013), angiogenesis (Spinazzi et al., 2006),
and increased release of metalloproteases (Zhou et al., 2012)
has previously been established. Interestingly, atherosclerotic
plaque instability is associated with increased inflammation
(Shah, 2014), angiogenesis (Lam et al., 2013), and extracellular
matrix protein degradation (Liu et al., 2014). Therefore, the
present findings suggest that initially UII contribute to vascular
calcification, however, sustained production and release of the
peptide could contribute to plaque instability.
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